Amalgamated Bank’s Entrada Therapeutics TRDA Stock Holding History

Amalgamated Bank’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-894	Closed	-$9K	–	2725
2025 Q4	$9K	Buy	894 +42	+5%	+$354	﹤0.01%	2491
2025 Q3	$5K	Hold	852	–	–	﹤0.01%	2800
2025 Q2	$6K	Hold	852	–	–	﹤0.01%	2693
2025 Q1	$8K	Buy	852 +131	+18%	+$1.63K	﹤0.01%	2493
2024 Q4	$12K	Hold	721	–	–	﹤0.01%	2367
2024 Q3	$12K	Hold	721	–	–	﹤0.01%	2378
2024 Q2	$10K	Hold	721	–	–	﹤0.01%	2470
2024 Q1	$10K	Sell	721 -1,145	-61%	-$16.2K	﹤0.01%	2461
2023 Q4	$28K	Sell	1,866 -215	-10%	-$3.19K	﹤0.01%	2505
2023 Q3	$33K	Hold	2,081	–	–	﹤0.01%	2433
2023 Q2	$32K	Buy	+2,081	New	+$28.7K	﹤0.01%	2505
2022 Q2	–	Sell	-1,350	Closed	-$13K	–	3199
2022 Q1	$13K	Buy	+1,350	New	+$14.5K	﹤0.01%	2916

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amalgamated Bank's TRDA Position: Q1 2026 in Review

Amalgamated Bank sold out of Entrada Therapeutics (TRDA) in Q1 2026, closing a stake of 894 shares — an estimated $9K sold.

Amalgamated Bank first reported a position in TRDA in Q1 2022 and held it in 12 quarters. The position peaked at $33K in Q3 2023. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

Amalgamated Bank reported no remaining Entrada Therapeutics position as of Q1 2026 after selling out during the quarter.
Amalgamated Bank sold 894 Entrada Therapeutics shares in Q1 2026, an estimated $9K.
Amalgamated Bank first reported a position in Entrada Therapeutics in Q1 2022 and held it in 12 quarters.
Amalgamated Bank's Entrada Therapeutics position peaked at $33K in Q3 2023.
120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.